Re: [NMusers] ASCO and pharmacometrics

From: Dennis Fisher <fisher_at_PLessThan.com>
Date: Thu, 7 Apr 2016 08:35:47 -0700

I agree with Phil. I have presented recently at two large endocrine =
meetings, one in the US, one in Europe. In both cases, I took =
complicated PK/PD models and kept it simple, emphasizing how the models =
could / would be used in clinical development and clinical practice. =
The response at both meetings was excellent — lots of people =
expressing interest in the models (and, interestingly, two of the =
competitors to the company for which I was consulting tried to enlist my =
consulting help).

And, I disagree with Nick’s comment yesterday. Perhaps oncology =
clinicians are concerned about commas (I cannot speak to that issue) but =
I truly doubt Nick’s claim that they don’t care about =
science — the advances in oncology in recent years have been =
remarkable.


Dennis Fisher MD
P < (The "P Less Than" Company)
Phone: 1-866-PLessThan (1-866-753-7784)
Fax: 1-866-PLessThan (1-866-753-7784)
www.PLessThan.com <http://www.plessthan.com/>



> On Apr 7, 2016, at 7:49 AM, Lowe, Phil <phil.lowe_at_novartis.com> wrote:
>
> I would echo Pascal’s point. Getting pharmacometric work into =
large clinical conferences is not straightforward. It can be done (see =
link)http://erj.ersjournals.com/content/46/suppl_59/PA5091.abstract =
<http://erj.ersjournals.com/content/46/suppl_59/PA5091.abstract> but =
note where I was in the author list as the sole modeller. It helps to =
work closely with the clinicians on the messaging. That said, it was fun =
at the meeting, explaining the data and model curves to clinicians with =
them asking how such knowledge could impact their patients. An =
eye-opener. Keep trying Naoto!
>
> All the best, Phil
>
> Philip J Lowe PhD
> Executive Director Pharmacometrics Scientist
> Novartis Pharma AG, WSJ-027.6.25 or WSJ-386.12.48.46
> 4056 Basel, Switzerland
> Phone: +41 61 324 4676
> phil.lowe_at_novartis.com <mailto:phil.lowe_at_novartis.com>
>
> From: owner-nmusers_at_globomaxnm.com =
<mailto:owner-nmusers_at_globomaxnm.com> =
[mailto:owner-nmusers_at_globomaxnm.com =
<mailto:owner-nmusers_at_globomaxnm.com>] On Behalf Of Pascal Girard
> Sent: 06 April 2016 10:39
> To: Naoto Hayashi; jgrevel_at_btconnect.com =
<mailto:jgrevel_at_btconnect.com>
> Cc: nmusers
> Subject: RE: [NMusers] ASCO and pharmacometrics
>
> Dear Naoto,
>
> In the past, Rene Bruno got one poster accepted with discussion at =
ASCO. He is our ”champion” !
>
> I got one accepted on model for Exp-Tumor Size – OS at =
European Cancer Congress 2013 . But I can tell you that a medical writer =
rewrote it entirely and it took 1 month to get it reviewed and corrected =
by clinicians challenging every comma and p-value.
>
> To give you an idea of the respective size of the meetings: ACOP =
N=500, PAGE N>600, ECC N> 10,000, ASCO N>20,000.
>
> So the advice I would give, is just improve the quality and =
readability of our abstract and it will make it. By readability, I mean =
show it to an oncologist clinician. If he does not understand, rewrite =
it with the help of a medical writer …
>
> With best regards / Mit freundlichen Grüßen / Cordialement
>
> Pascal


Received on Thu Apr 07 2016 - 11:35:47 EDT

This archive was generated by hypermail 2.3.0 : Fri Sep 27 2019 - 16:49:49 EDT